Core Viewpoint - The company is actively addressing regulatory concerns raised by the China Securities Regulatory Commission (CSRC) through comprehensive reforms and a commitment to long-term compliance and risk management [1][2][4]. Group 1: Regulatory Response and Reform - The company has initiated a thorough review and rectification process in response to issues identified by the CSRC, emphasizing principles such as "fact-based assessment" and "long-term control" [1]. - A specialized meeting was convened by the chairman to analyze risks associated with research contracts and to establish clear responsibilities for rectification [2]. - The company has already recovered all advance payments related to terminated research projects due to issues with technology transfer [1]. Group 2: Contract and Project Management Improvements - The company is revising and enhancing its contract templates and audit processes to ensure compliance and establish a long-term rectification mechanism [2]. - A comprehensive risk management framework for research projects has been developed, including the hiring of external consultants to guide the transformation of the research system [2]. - The company has completed major rectification tasks, including the optimization of contract review processes and the establishment of a risk control mechanism for research projects [2]. Group 3: Long-term Compliance and Training Initiatives - The company is building a long-term compliance management system to ensure strict operational standards and a shift towards proactive risk management [3]. - A series of targeted training sessions have been conducted to enhance compliance awareness among employees, covering areas such as contract management and risk prevention [3]. - The company aims to transform compliance and internal control into a value driver, enhancing operational quality and market competitiveness in a stricter regulatory environment [4].
津药药业历史问题出清中,长效合规体系稳步构建